• Informing Precision Treatment Approaches for Breast Cancer

    Breast cancer is an important example of how a better understanding of cancer biology can lead to more personalized and precise treatments that improve patient care and prognosis. Surgery, hormone therapy, and chemotherapy were the standard of care for decades, but research into the HER2 gene as a potential …

    Continue Reading

  • Tumor Mutational Burden (TMB) Could Help Predict Response to Immunotherapy

    Tumor mutational burden (TMB) is a genomic biomarker with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to checkpoint inhibitor …

    Continue Reading

  • Improving Clinical Trial Design with Tumor Mutational Burden (TMB)

    Biomarkers are playing a transformative role in cancer drug development. Not only can they help identify patients most likely to respond to a medicine, they can also make a huge difference in drug development by improving outcomes in clinical trials. Just as the right biomarker can positively influence drug response …

    Continue Reading

  • Trials and Outcomes: Accelerating Precision Medicine at ASCO 2017

    At Foundation Medicine, our vision for precision oncology is based on fundamentally changing the way patients receive care. For us, this means enabling practical and clinically applicable solutions, no matter the stage or composition of the cancer, and regardless of where the patient lives or is being …

    Continue Reading

  • Unleashing the Potential of Clinico-Genomic Information: ASCO 2017

    Precision oncology requires a robust understanding of how genomic information relates to clinical outcomes and treatment response. To make this connection, we need to integrate multiple sources of data into single databases that have the power to inform new clinical insights. This has historically been difficult …

    Continue Reading

  • At ASCO 2017, Foundation Medicine is presenting new comprehensive genomic profiling data spanning 15 different tumor types. Learn more about the insights FoundationOne® can provide for both targeted therapies and immunotherapies across a range of different cancers. Learn more about our posters and presentations at …

    Continue Reading

  • This week was the American Association for Cancer Research (AACR) annual meeting in Washington, DC. As we followed the event, we identified the 140-character anecdotes and quotes that shine a light on emerging trends in cancer research. Cancer immunotherapy continues to be a hot topic. While the treatment landscape …

    Continue Reading

  • Diving Deeper Into Cancer Immunotherapy Biomarkers

    Cancer immunotherapy is transforming the treatment landscape for many types of cancer, but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field. Personalized targeted therapies have traditionally been prescribed based on the presence of single …

    Continue Reading

  • Completing the Puzzle for Colorectal Cancer

    Each person and each cancer is unique, and the goal of precision medicine is to uncover this individuality. For colorectal cancer (CRC), we have discovered a few important pieces of the puzzle, but the entire picture is incomplete. There is an urgent need to discover more specific predictive markers of CRC that can …

    Continue Reading

  • A child getting diagnosed with cancer is devastating and can often be compounded by not knowing how to help, or what to do next. Many pediatric cancers are still not well understood, and it remains the leading cause of death by disease among children in the United States.1 Fortunately, advances in research have …

    Continue Reading